Article Text

other Versions

PDF
Testing for JAK2 V617F Mutation Across Specimen Types Yields Concordant Results
  1. Imran Mirza (imirza{at}cha.ab.ca)
  1. University of Alberta, Canada
    1. Donna Sekora (donna.sekora{at}capitalhealth.ca)
    1. University of Alberta, Canada
      1. Christine Frantz (christine.frantz{at}capitalhealth.ca)
      1. University of Alberta, Canada

        Abstract

        Chronic myeloproliferative neoplasms (CMPN) are a group of hematopoietic stem cell disorders associated with abnormal blood cell production and bone marrow (BM) morphology. Myeloid cells from the majority of polycythemia vera (PV) patients and approximately half of essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients carry the JAK2 V617F mutation.1-3 Recent proposed revisions to the World Health Organization (WHO) diagnostic criteria for these disorders include the presence of JAK2V617F mutation as a major criterion for diagnosis.4 Although various studies have shown that JAK2 mutation testing can be successfully performed on peripheral blood (PB),1-3 bone marrow aspirate (BMA),5 or BM biopsy,6, 7 comparison of results across different sample types has not been performed.

        Statistics from Altmetric.com

        Request permissions

        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.